Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540161 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Annick Desjardins.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02540161 is a Phase 2 study that has completed, run by Annick Desjardins. The registered enrollment target is 43 participants.
The verdict
NCT02540161, a Phase 2 study, has completed, sponsored by Annick Desjardins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified. This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glioma (glioblastoma or gliosarcoma) in two cohorts to assess the efficacy of Sym004.
Interventions
- DRUG Sym004 - 18 mg/kg
- DRUG Sym004 - 24 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02540161
The ClinicalTrials.gov registry entry for NCT02540161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annick Desjardins, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sym004 - 18 mg/kg is the first listed.
NCT02540161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02540161 about?
NCT02540161 is a clinical study titled "Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma". The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified. This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glio...
What is the current status of trial NCT02540161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-02-01. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT02540161?
The interventions under investigation include: Sym004 - 18 mg/kg (DRUG), Sym004 - 24 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02540161?
This trial is sponsored by Annick Desjardins, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.